Showing results (291-300 of 303) with videos related to
Sort By:
Pageof 31
Cell Reports|December 1, 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatmentJennifer E Klomp, Ye S Lee, Craig M Goodwin, et al.Cancer Discovery|October 26, 2019
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic CancerG Aaron Hobbs, Nicole M Baker, Anne M Miermont, et al.Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.Science (New York, N.Y.)|June 6, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersJeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, et al.Cell Reports|June 30, 2021
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.Cancer Cell|June 20, 2020
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic CancerLuisa F Escobar-Hoyos, Alex Penson, Ram Kannan, et al.Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.Pageof 31